Radar › Companies › Gastroenterology · Massachusetts
Radar · Gastroenterology in Massachusetts

Best Gastroenterology Companies in Massachusetts, United States

The 30 best Gastroenterology companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ironwood Pharma.

30companies tracked
$1.5Bdisclosed funding
0unicorns
20have raised

Ranked: Best Gastroenterology companies in Massachusetts

#CompanyDisclosed fundingLast roundEmployeesFoundedFounderTech stackPatents & IP focusRecent signals
1Ironwood Pharma
Developer of therapeutics for gastrointestinal disorders
$206M87 mo ago2201998Thomas Mccourt
CEO
WordPressApple iCloud MailMySQL+27——
2Finch Therapeutics
Developer of microbiome-based therapies by using human-first discovery platform
$184M74 mo ago182004Tom Borody
Co-Founder
—129 patents
Microbiome-based therapeutics for gastrointestinal and neurodevelopmental disorders
—
3Gelesis
Satiety induction through hydrogel capsules
$182M83 mo ago932006Yishai Zohar
Founder & CEO
PleskPHPVimeo+15173 patents
Hydrogel-based oral medical devices for obesity, constipation, and microbiome modulation
—
4Evelo Biosciences
Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer
$167M40 mo ago1172015Simba Gill
CEO
—385 patents
Microbiome‑based therapeutics using bacterial and extracellular vesicle formulations
—
5Seres Therapeutics
Developer of microbiome therapeutics to treat a wide range of diseases
$134M29 mo ago3322010David Berry
Founder
DrupalApple iCloud MailMicrosoft 365+24274 patents
Therapeutic live bacterial formulations for gut microbiome modulation and infection/cancer treatment
—
6NinePoint Medical
Advanced medical imaging for real-time tissue microstructure visualization and analysis
$98M131 mo ago252008————
7Alcresta
Developer of enzyme-based products for gastrointestinal disorders
$96M80 mo ago52
52 → 106 (+104%)
2011——41 patents
Targeted dietary fatty acid delivery systems for nutritional supplementation
—
8Synta Pharmaceuticals
Small molecule drugs for cancer and chronic inflammatory conditions
$90M187 mo ago372000——1,214 patents
HSP90 inhibitor combination therapies targeting ovarian and other cancers
—
9Axcella
Developer of targeted therapeutics for infectious and metabolic disorders
$87M113 mo ago112008————
10Auron Therapeutics
Developer of cancer therapeutics for the treatment of blood cancer
$63M21 mo ago272018Kate Yen
Co-Founder & CEO
WebflowApple iCloud MailZendesk+11——
11Dynogen Pharmaceuticals
5HT3 receptor-targeted drugs for bowel syndromes
$63M271 mo ago——————
12Solarea Bio
Innovating microbial solutions for human health, focusing on aging well
29Funding top 29%Moat top 39%Tech top 43%News top 44%
All 7 signals ▾
Fundingtop 29%
Moattop 39%
Techtop 43%
Newstop 44%
Talentbottom 49%
Globalbottom 36%
Marketbottom 29%
Funding: Raised $27.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
rank vs industry peers · Fliar Intelligence Index 29/100
$27M12 mo ago242017Gerardo Toledo
Co-Founder & CEO
SanityNode.jsHeadless UI+9——
13AltrixBio
Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases
$13M14 mo ago52019——2 patents
Mucoadhesive drug delivery systems for targeted mucosal administration of active agents
—
14Suono Bio
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract
$13M38 mo ago132015C Traverso
Co-Founder
———
15ColonaryConcepts
Online casino offering diverse games, bonuses, and secure access
$13M77 mo ago12013Herb Stern
Founder & CEO
—60 patents
Gastrointestinal pharma formulations for constipation, PEG assay kits, and electrolyte replacement foods
—
16Olympus Endotechnology America
Endoscope insertion devices for Gastrointestinal and Cardiovascular procedures
$8M233 mo ago—2005Steven Tallarida
CEO
———
17Anagram
Developer of therapeutics for metabolic diseases
$8M6 mo ago202017Robert Gallotto
President and Chief Executive Officer
———
18Blue Therapeutics
Developer of small molecule drugs for neurological disorders
$7M66 mo ago42014Ajay Yekkirala
Co-Founder & CSO
———
19Trine Pharmaceuticals
Small molecule drugs for gastrointestinal and metabolic diseases
$6M255 mo ago—1992Mark Skaletsky
CEO
———
20LAPIX
Developer of immunotherapies for immunological diseases
$3M16 mo ago92019Anas Fathallah
Co-Founder & CEO
WordPressMySQLPHP+16——
21Bilayer Therapeutics
Developer of therapeutics for gastrointestinal diseases
$2M39 mo ago42020Thomas Collet
CEO & President
———
22Oasis Pharmaceuticals
Developer of therapeutics to treat inflammatory, fibrotic, and metabolic disorders
$2M18 mo ago—2013Lidija Covic
Founder & CSO
———
23EnVision Endoscopy
Developer of devices for gastrointestinal endoscopic surgery
$556K75 mo ago62018Azadeh Khanicheh
Co-Founder
—48 patents
Minimally invasive endoscopic suturing devices and accessories for gastrointestinal surgery
—

Top 12 Gastroenterology companies in Massachusetts

#1
Series B · Natick, Massachusetts · founded 2017 · 20 employees
$8.2Mraised
▾

Developer of therapeutics for metabolic diseases. It offers orally-delivered enzymes as therapies for malabsorption syndrome and nutrient metabolism disorders which is s caused by enzyme deficiencies or genetic mutations.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 6.8% of this cohort's audience
Funding rounds
  • May 2026Series B$250M
  • Aug 2022Grant (prize money)$1.8M
  • Jan 2018Grant (prize money)$3M
  • Aug 2017Series A$8.2M
Founders & team
Robert GallottoPresident and Chief Executive Officer
Investors
Cystic Fibrosis Foundation, HHS, Blackstone
#2
Series B · Cambridge, Massachusetts · founded 2017 · 24 employees
$27.3Mraised
▾

Innovating microbial solutions for human health, focusing on aging well. The company rapidly innovates and delivers breakthrough solutions for unmet medical needs, particularly in aging health. They are committed to advancing health outcomes through microbial science. Their core values include integrity, scientific rigor, diversity and inclusion, tenacity, a sense of purpose, transparency, and innovation. They develop products to address dietary needs related to rheumatoid arthritis, psoriatic arthritis, and cellular aging. The company uses a rigorous process involving discovery, development, preclinical testing, and clinical trials. They aim to provide trustworthy solutions for health conditions, incorporating the highest level of scientific rigor into every aspect of their process. They are dedicated to improving collective health outcomes and providing transparent formulations.

Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 29%
Moat
top 39%
Tech
top 43%
News
top 44%
Talent
bottom 49%
Global
bottom 36%
Funding: Raised $27.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) · Last round Series B (Nov 2025)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Tech: 25 technologies across 4/8 capability areas · Cloud: Vercel · Security: Hsts
Audience (LinkedIn): 2k LinkedIn followers — 5.6% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 1 awards announced in 12 mo
Funding rounds
  • Nov 2025Series B$9.9M
  • Aug 2024Series B$1M
  • May 2023Series B$15M
  • Sep 2020Series A$11.3M
Founders & team
Gerardo ToledoCo-Founder & CEO
Investors
Illumina, Bold Capital Partners, Viking Global Investors, GISEV, S2G Investments, GG1978
Tech stack
WordpressMysqlPhpWp RocketContact Form 7Yoast Seo
#3
Series B · Wellesley, Massachusetts · founded 2018 · 27 employees
$63.4Mraised
▾

Developer of cancer therapeutics for the treatment of blood cancer. The company has developed its proprietary differentiation therapy used for the treatment of hematologic malignancies. It helps in reactivating endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a normal phenotype. It can be used to treat acute promyelocytic leukemia (APL) by differentiating malignant promyelocytes into non-cancerous cell neutrophils.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 8.3% of this cohort's audience
Funding rounds
  • Feb 2025Series B$27M
  • Dec 2024Series B$27.3M
  • Jul 2022Series A$48M
  • Dec 2020Seed$15.4M
Founders & team
Kate YenCo-Founder & CEOMatt HeidenCo-FounderEytan SteinCo-Founder
Investors
Creyon Bio, Totus Medicines, Genedit, Mubadala, Apollo Health Ventures, Arkin Holdings
#4
Series A · Cambridge, Massachusetts · founded 2019 · 5 employees
$12.8Mraised
▾

Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases. The company has developed drug candidate LuCI that helps in the treatment of gastrointestinal (GI) tract infections and also modulates nutrient contact with the bowel mucosa. It has developed drugs that help in treating diabetes and also reduces fats and glucose levels of the body.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 889 LinkedIn followers — 2.0% of this cohort's audience
Funding rounds
  • Sep 2025Series A$5M
  • Apr 2025Series A$1.2M
  • Mar 2019Series A$6.6M
Investors
100 Plus Capital, XFactor Ventures, Taihill Venture
#5
Public · Cambridge, Massachusetts · founded 2010 · 332 employees
$134.1Mraised
▾

Developer of microbiome therapeutics to treat a wide range of diseases. The product pipeline includes SER-109 for C. difficile infection (CDI), SER-155 for antibiotic-resistant infections and GvHD, and SER 287 for ulcerative colitis.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 26k LinkedIn followers — 58.9% of this cohort's audience · 64 engagements/post (3.1× cohort median)
Funding rounds
  • 2024Post IPO—
  • Nov 2017Grant (prize money)$2.5M
  • Dec 2014Series D$65M
  • Nov 2014Series C$48M
Founders & team
David BerryFounderEric ShaffPresident
Investors
Enso Ventures, Alexandria, Flagship Pioneering, Mayo Clinic Business Accelerator, CARB-X, Nestlé Health Science
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#6
Series A · Boston, Massachusetts · founded 2019 · 9 employees
$3.5Mraised
▾

Developer of immunotherapies for immunological diseases. It offers a lead candidate LPX-TI641 for multiple sclerosis, Neuromyelitis Optica, Rheumatology, LPX-TIIBD for Inflammatory bowel disease, and also provides gene therapy.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers — 3.2% of this cohort's audience
Activity: 1 product launches announced in 12 mo
Funding rounds
  • Jul 2025Series A$2.2M
  • Aug 2024Series A$5.5M
  • Oct 2022Seed$1.2M
Founders & team
Anas FathallahCo-Founder & CEOJason NorrisCo-Founder
#7
Public · Cambridge, Massachusetts · founded 2015 · 117 employees
$166.5Mraised
▾

Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.

Funding rounds
  • Jul 2023Post IPO$25.5M
  • Mar 2018Series C$81.5M
  • Jul 2017Series B$50M
  • Nov 2015Series A$35M
Founders & team
Simba GillCEO
Investors
Flagship Pioneering, Google Ventures, Celgene, Acks, Mayo Clinic Ventures, SV Health Investors
#8
Funding Raised · Boston, Massachusetts · founded 2013
$2Mraised
▾

Oasis Pharmaceuticals is a developer of therapeutic agents for inflammatory, fibrotic and metabolic disorders. The products developed are OA-235i to treat NASH (in phase I), OA-3 hydrogel to treat AD/pruritus (in phase I), and OA-235c to treat IPF (in preclinical stage).

Funding rounds
  • May 2025Grant (prize money)$2M
Founders & team
Lidija CovicFounder & CSOAthan KuliopulosFounder & CEODana MinnickFounder
Investors
HHS
#9
Public · Somerville, Massachusetts · founded 2004 · 18 employees
$184Mraised
▾

Finch Therapeutics is a developer of microbiome-based therapies using a human-first discovery platform. It is using proprietary machine learning techniques to build a clinically annotated library of strains that drive clinical phenotypes of interest. It has also developed an AquaShell for targeted delivery of microbial therapeutics. Its products mainly focussed on Inflammatory Bowel Disease (preclinical), and others.

Funding rounds
  • Sep 2020Series D$90M
  • Jul 2019Series C$53.5M
  • Mar 2018Series B$36M
  • Jan 2017Series A$3.7M
Founders & team
Tom BorodyCo-FounderZain KassamCo-FounderJared BurgessCo-Founder
Investors
OMX Ventures, Octave Group, MSD Partners, MSD Capital, Humboldt Fund, The Baupost Group
#10
Public · Cambridge, Massachusetts · founded 1998 · 220 employees
$206.3Mraised
▾

Developer of therapeutics for gastrointestinal disorders. The company's lead product linaclotide is a guanylate cyclase-C (GC-C) agonist, which is indicated for irritable bowel syndrome with constipation and chronic idiopathic constipation. Also, it offers applications for pediatric GI diseases.

Funding rounds
  • Aug 2019Post IPO$341M
  • Nov 2009Series F$15M
  • Sep 2009Series F$25M
  • Aug 2009Series F$250K
Founders & team
Thomas MccourtCEO
Investors
Morgan Stanley, Ridgeback Capital Management, Invus, EDBI, Venrock, Polaris Partners
Tech stack
Amazon SesAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementCore-Js
#11
Public · Boston, Massachusetts · founded 2006 · 93 employees
$182.5Mraised
▾

Gelesis develops technologies for the treatment of obesity and other unmet medical needs. It offers Attiva, a superabsorbent hydrogel composed entirely from food components, is administered in the form of small particles that are designed to swell after ingestion with water, and occupy the gastric and intestinal cavities, inducing a feeling of satiety that lasts beyond its transit time in the stomach.

Funding rounds
  • Dec 2019Conventional Debt$8.3M
  • Dec 2019Grant (prize money)$12.9M
  • Dec 2019Series D$63.4M
  • Apr 2019Grant (prize money)$10.6M
Founders & team
Yishai ZoharFounder & CEO
Investors
PureTech Health, Vitruvian Partners, Europa, BIRD Foundation, Suffolk Equity Partners, Hercules Capital
Tech stack
Apache Http ServerBootstrapCloudflareCloudflare Bot ManagementContact Form 7Elementor
#12
Acquired · Newton, Massachusetts · founded 2011 · 52 employees
$95.9Mraised
▾

Developer of enzyme-based products for gastrointestinal disorders. Its platform technology immobilizes enzymes and attaches them to an insoluble carrier, that can be used to support the digestion and absorption of essential nutrients. Its flagship product Relizorb is a digestive enzyme cartridge that has been designed to mimic the function of pancreatic lipase.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 7.7% of this cohort's audience
Funding rounds
  • Feb 2020Series D$10M
  • Jan 2019Series D$5M
  • Sep 2017Series D$10M
  • Mar 2016Series C$50.9M
Investors
Third Rock Ventures, Frazier Healthcare Partners, Bessemer Venture Partners, Athyrium Capital Management, Health Quest Capital, Frazier Life Sciences
Tech stack
CloudflareHttp/3

Funding & investor landscape

$1.5Btotal disclosed funding
23companies funded
94disclosed rounds
0rounds last 90 days
Most active investors
Flagship Pioneering4 rounds
HHS3 rounds
Polaris Partners3 rounds
SV Health Investors3 rounds
Athyrium Capital Management2 rounds
Enso Ventures2 rounds
Hercules Capital2 rounds
Ludicrous Ventures2 rounds
MassChallenge2 rounds
Nestlé Health Science2 rounds

Notable founders

Robert Gallotto
President and Chief Executive Officer · Anagram
Gerardo Toledo
Co-Founder & CEO · Solarea Bio
Kate Yen
Co-Founder & CEO · Auron Therapeutics
Matt Heiden
Co-Founder · Auron Therapeutics
David Berry
Founder · Seres Therapeutics
Eric Shaff
President · Seres Therapeutics
Anas Fathallah
Co-Founder & CEO · LAPIX
Jason Norris
Co-Founder · LAPIX
Simba Gill
CEO · Evelo Biosciences
Lidija Covic
Founder & CSO · Oasis Pharmaceuticals
Athan Kuliopulos
Founder & CEO · Oasis Pharmaceuticals
Tom Borody
Co-Founder · Finch Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 11,095,885 docs

Market landscape — 10 sub-themes by coverage

Share of Gastroenterology coverage by sub-theme.

Regulatory-risk over time flat

Funding & growth over time

funding rising · growth rising

Common questions

How many Gastroenterology companies are there in Massachusetts, United States?
Radar tracks 30 indexable Gastroenterology companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Gastroenterology companies in Massachusetts, United States?
The Gastroenterology companies in Massachusetts, United States on this list have raised a combined $1.5B in disclosed equity funding across 23 funded companies.
Which is the highest-funded Gastroenterology company in Massachusetts, United States?
Ironwood Pharma is the highest-funded Gastroenterology company in Massachusetts, United States, with $206.3M in disclosed equity funding.
How many Gastroenterology companies in Massachusetts, United States are funded?
23 of the 30 Gastroenterology companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Gastroenterology unicorns are there in Massachusetts, United States?
None of the Gastroenterology companies in Massachusetts, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Massachusetts, United States Gastroenterology companies?
The most active investors in Massachusetts, United States Gastroenterology companies on this list include Flagship Pioneering, HHS, Polaris Partners, SV Health Investors, Athyrium Capital Management.
Riya SenguptaFinancials

Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.

Coming soon